Last reviewed · How we verify

NCT05086991: AIHEMAF - P

AIHEMAF - P "An Innovative Healthcare Model for AF Patients"

Completed Last updated 10 October 2023
What this trial tests

trial testing Follow up in Atrial Fibrillation in 50 participants. Completed in 1 April 2023.

Timeline
1 October 2021
Primary endpoint
1 April 2023
1 April 2023

Quick facts

Lead sponsorFarmacia La Regina s.r.l.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment50
Start date1 October 2021
Primary completion1 April 2023
Estimated completion1 April 2023
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Farmacia La Regina s.r.l.

Who can join

Eligibility, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Non-profit observational study on the role of the community pharmacist and "the pharmacy of services" in the case management of patients suffering from atrial fibrillation and being treated with new generation oral anticoagulants

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. AIHEMAF-P: An Innovative Healthcare Model for Atrial Fibrillation Patients.
    La Regina R, Innelli P, Glisenti F, Bollani G, et al · · 2024 · PMID 39728852 · DOI 10.3390/pharmacy12060187

Verify or expand the search:

Other trials of Follow up

Trials testing the same drug.

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Farmacia La Regina s.r.l. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05086991.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing